A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria

Margaret A. Phillips, Karen L. White, Sreekanth Kokkonda, Xiaoyi Deng, John White, Farah El Mazouni, Kennan Marsh, Diana R. Tomchick, Krishne Manjalanagara, Kakali Rani Rudra, Grennady Wirjanata, Rintis Noviyanti, Ric N. Price, Jutta Marfurt, David M. Shackleford, Francis C. K. Chiu, Michael Campbell, Maria Belen Jimenez-Diaz, Santiago Ferrer Bazaga, Iñigo Angulo-Barturen, Maria Santos Martinez, Maria Lafuente-Monasterio, Werner Kaminsky, Kigbafori Silue, Anne-Marie Zeeman, Clemens Kocken, Didier Leroy, Benjamin Blasco, Emilie Rossignol, Thomas Rueckle, Dave Matthews, Jeremy N. Burrows, David Waterson, Michael J. Palmer, Pradipsinh K. Rathod, Susan A. Charman
  • ACS Infectious Diseases, October 2016, American Chemical Society (ACS)
  • DOI: 10.1021/acsinfecdis.6b00144

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1021/acsinfecdis.6b00144

The following have contributed to this page: Professor Diana R. Tomchick